Opiant Pharmaceuticals Inc (OPNT)

40.58
NASDAQ : Health Care
Prev Close 36.97
Day Low/High 37.15 / 41.94
52 Wk Low/High 5.00 / 51.90
Avg Volume 62.70K
Exchange NASDAQ
Shares Outstanding 2.03M
Market Cap 74.92M
EPS -6.60
P/E Ratio 12.62
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FUNC, HAIN, PRCP, SHEN, SSNT Downgrades: AVAV, CLDT, PAG, TLF, TOWR Initiations: OPNT, TLND Read on to get TheStreet Quant Ratings' detailed report:

Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization

Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization

Company Received Additional Payment From SWK Funding LLC Based on Achievement of $25 Million Net Sales of NARCAN® Nasal Spray Milestone

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing For New NARCAN® Nasal Spray Patent

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing For New NARCAN® Nasal Spray Patent

Listing Strengthens IP Position and Enhances NARCAN Product Exclusivity

Opiant Pharmaceuticals Looks to Create a Heroin Vaccine and Treat Addictions

Opiant Pharmaceuticals Looks to Create a Heroin Vaccine and Treat Addictions

Overdoses kill 91 people a day.

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing For New NARCAN® Nasal Spray Patent

Listing Bolsters IP Estate and Enhances NARCAN Product Exclusivity

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings For Two New NARCAN® Nasal Spray Patents

Listings Significantly Strengthen IP Estate and Enhance NARCAN Product Exclusivity

Opiant Pharmaceuticals, Inc. Receives FDA Feedback Supporting Clinical Development Of OPNT002 For The Treatment Of Alcohol Use Disorder

Company Plans Additional Clinical Trials This Year; Topline Data Expected in 2018

Opiant Pharmaceuticals, Inc. Announces Establishment Of Audit, Compensation And Nominating And Corporate Governance Committees

Company to pursue up-listing to a major stock exchange in 2017

Opiant Pharmaceuticals, Inc. Announces FDA Approval Of 2mg Formulation Of NARCAN (naloxone HCI) Nasal Spray

Opiant Pharmaceuticals, Inc. Announces FDA Approval Of 2mg Formulation Of NARCAN (naloxone HCI) Nasal Spray

2mg Formulation Indicated for Patients At-Risk for Severe Opioid Withdrawal

Opiant Pharmaceuticals, Inc. Announces NARCAN® Nasal Spray Royalty Monetization

Opiant Pharmaceuticals, Inc. Announces NARCAN® Nasal Spray Royalty Monetization

SWK to Acquire Certain NARCAN® Royalties For Up to $17.5 Million

Opiant Pharmaceuticals, Inc. Announces Appointment Of Thomas T. Thomas To Board Of Directors

Opiant Pharmaceuticals, Inc. Announces Appointment Of Thomas T. Thomas To Board Of Directors

Thomas Brings Global Pharmaceutical and Financial Expertise to Opiant's Board

TheStreet Quant Rating: C+ (Hold)